Gabriel Leung has been an independent member of our Board and has served as Chairman of the Nominating and Corporate Governance Committee since November 2016. He also serves on our Audit Committee. Since 2011, Mr. Leung has served as the Vice Chairman and a member of the board of directors of NovoCure Limited, a publicly listed commercial-stage oncology company. Previously he was Executive Vice President of OSI Pharmaceuticals, Inc., or OSI, and President of OSI’s Oncology and Diabetes Business, from 2003 to 2010, prior to its acquisition by Astellas Pharma Inc. At OSI, Mr. Leung was responsible for the launch of erlotinib, or Tarceva. Prior to his tenure at OSI, from 1999 to 2003, Mr. Leung served as Group Vice President of the global prescription business at Pharmacia Corporation. From 1991 to 1999, Mr. Leung was an executive at Bristol-Myers Squibb Company. In addition, Mr. Leung served as a director for Albany Molecular Research Inc., a global contract research and manufacturing company, from 2010 to 2016 and as a director of Delcath from 2011 to 2015. Mr. Leung earned his B.S. in Pharmacy with high honors at the University of Texas at Austin. Mr. Leung attended graduate school at the University of Wisconsin-Madison, where he earned his M.S. in Pharmacy, with a concentration in pharmaceutical marketing.